Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

Overall survival and response rates of 270 patients with newly diagnosed acute myeloid leukemia receiving venetoclax (Ven) plus hypomethylating agent, stratified by Ven dosing schedule (Cycle 1 Ven 14 vs. 21 vs. 28 days).

Saved in:
Bibliographic Details
Published in:American journal of hematology 2024-02, Vol.99 (2), p.E63-E66
Main Authors: Karrar, Omer, Abdelmagid, Maymona, Rana, Masooma, Iftikhar, Moazah, McCullough, Kristen, Al‐Kali, Aref, Alkhateeb, Hassan B., Begna, Kebede H., Elliott, Michelle A., Mangaonkar, Abhishek, Saliba, Antoine, Hefazi Torghabeh, Mehrdad, Litzow, Mark R., Hogan, William, Shah, Mithun, Patnaik, Mrinal M., Pardanani, Animesh, Badar, Talha, Murthy, Hemant, Foran, James, Palmer, Jeanne, Sproat, Lisa, Khera, Nandita, Arana Yi, Cecilia, Tefferi, Ayalew, Gangat, Naseema
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Bridged Bicyclo Compounds, Heterocyclic - adverse effects
Comparative analysis
Hematology
Humans
Leukemia, Myeloid, Acute - drug therapy
Sulfonamides - adverse effects
Survival
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Overall survival and response rates of 270 patients with newly diagnosed acute myeloid leukemia receiving venetoclax (Ven) plus hypomethylating agent, stratified by Ven dosing schedule (Cycle 1 Ven 14 vs. 21 vs. 28 days).
ISSN:0361-8609
1096-8652
1096-8652
DOI:10.1002/ajh.27180